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ABSTRACT
Objective The aim of this review was to summarise the 
current evidence on the costing of resource use within 
UK maternity care, in order to facilitate the estimation 
of incremental resource and cost impacts potentially 
attributable to maternity care interventions.
Methods A systematic review of economic evaluations 
was conducted by searching Medline, the Health 
Management Information Consortium, the National Health 
Service (NHS) Economic Evaluations Database, CINAHL 
and National Institute for Health and Care Excellence (NICE) 
guidelines for economic evaluations within UK maternity 
care, published between January 2010 and August 2019 
in the English language. Unit costs for healthcare activities 
provided to women within the antenatal, intrapartum 
and postnatal period were inflated to 2018–2019 prices. 
Assessment of study quality was performed using the 
Quality of Health Economic Analyses checklist.
Results Of 5084 titles or full texts screened, 37 papers 
were included in the final review (27 primary research 
articles, 7 review articles and 3 economic evaluations from 
NICE guidelines). Of the 27 primary research articles, 21 
were scored as high quality, 3 as medium quality and 3 
were low quality. Variation was noted in cost estimates 
for healthcare activities throughout the maternity care 
pathway: for midwife- led outpatient appointment, the 
range was £27.34–£146.25 (mean £81.78), emergency 
caesarean section, range was £1056.44–£4982.21 (mean 
£3508.93) and postnatal admission, range was £103.00–
£870.10 per day (mean £469.55).
Conclusions Wide variation exists in costs applied to 
maternity healthcare activities, resulting in challenges in 
attributing cost to maternity activities. The level of variation 
in cost calculations is likely to reflect the uncertainty 
within the system and must be dealt with by conducting 
sensitivity analyses. Nationally agreed prices for granular 
unit costs are needed to standardise cost- effectiveness 
evaluations of new interventions within maternity care, 
to be used either for research purposes or decisions 
regarding national intervention uptake.
PROSPERO registration number CRD42019145309.
BACKGROUND
Healthcare economic evaluations are perti-
nent components of healthcare research 
and quality improvement, informing policy-
makers on the cost- effectiveness of new inter-
ventions and thereby assisting in decisions 
regarding their uptake. The UK National 
Institute for Health and Care Excellence 
(NICE) bases its recommendations on 
the implementation of new interventions 
according to both their clinical efficacy and 
cost- effectiveness.1 The number of cost- 
effectiveness evaluations published annually 
in obstetrics and gynaecology has increased 
Strengths and limitations of this study
 ► This systematic review is the first to compare pub-
lished unit costs for the different healthcare activi-
ties that may be offered to women in the UK during 
antenatal, intrapartum and postnatal care.
 ► A comprehensive search was conducted in four 
databases; unit costs extracted from published 
research articles were compared with one anoth-
er and with summary costs published as part of 
review articles (mostly national Health Technology 
Assessments) and guidelines.
 ► The search was limited to reports published since 
January 2010 (to ensure the data was contempora-
neous) and studies conducted in the UK.
 ► Unit costs were extracted for common or presumed 
high- cost activities within the maternity pathway, 
where the frequency of use was expected to vary 
with implementation of new antenatal or intrapar-
tum interventions; low- cost interventions, for which 
the frequency of use was not expected to vary, were 
not costed.
 ► Unit costs extracted from published reports of 
economic evaluations were inflated to 2018/2019 
prices and stratified by quoted cost perspective to 
ensure comparability.
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since 2000, with the majority being conducted alongside 
a clinical trial.2
Internationally, maternity care is funded using 
different payment models, including itemised bills and 
payment using composite ‘bundled’ costs.3–5 Bundled 
pricing describes a model where a single price is used 
to cover a full package of care for a specific indica-
tion. Bundled costs can be uplifted locally using factors 
that account for geographical variation in the cost 
of providing care and by the level of comorbidity or 
complexity of the woman and her pregnancy, but are not 
explicitly changed by differences in utilisation of mater-
nity services.4 6 Such models are often used because they 
are easier for hospitals to manage, allow flexibility within 
the pathway and are intended to encourage improve-
ments in care including standardisation of evidence- 
based care.3 Bundled payments were introduced by 
the Medicaid initiative (USA) to also reduce interven-
tions that are not medically indicated and potentially 
harmful.5 Bundled payment models are also used for 
non- maternity indications.7
While bundled costs represent the cost of a woman’s 
care to a commissioner or insurer, to the hospital they 
only reflect the average cost of women who experience 
the same level of complexity in pregnancy. Bundled 
payments present difficulties in estimating small changes 
to the overall cost of a woman’s maternity care as a result 
of a new intervention, because the cost of her care is esti-
mated as a composite, which is often not affected by small 
changes in resource use (eg, additional antenatal appoint-
ments or ultrasound scans). This represents a significant 
limitation for using these tariffs in estimating costs within 
economic evaluations, which seek to identify the true 
clinical resource impact of initiatives aimed at improving 
quality of maternal and perinatal care, as distinct from 
potential financial impacts to commissioners or insurers.
The aim of this review was to summarise the current 
evidence on the costing of resource use within UK mater-
nity care, in order to facilitate the estimation of incre-
mental resource and cost impacts potentially attributable 
to maternity care interventions.
METHODS
This review was registered on PROSPERO during the 
data collection stage. The report has been written using 
the Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses guidelines; the checklist has been included 
in online supplemental file 1.
Search strategy
A systematic review was conducted in August 2019 of the 
Medline, Health Management Information Consortium, 
the National Health Service (NHS) Economic Evalua-
tions Database, CINAHL database and National Institute 
for Health and Care Excellence (NICE) guidelines for 
economic evaluations of maternity care and the economic 
impact of research interventions. Search terms included 
free text and expanded synonyms for terms relevant to 
economic evaluations (eg, cost- effectiveness and price 
tariffs) and to pregnancy healthcare (eg, midwife, mater-
nity and pregnancy). The full search strategy is included 
within online supplemental file 2. The search was limited 
to papers written in the English language (because the 
perspective was that of UK maternity care providers) and 
published since 2010 (to ensure the cost estimations were 
recent and more reliable when inflated to current prices).
For inclusion in the review, it was predetermined that 
papers must be full reports of primary research studies or 
systematic reviews (including those in NICE guidelines), 
where an economic evaluation of an antenatal or intra-
partum intervention was performed and assessed within 
the UK context only. A UK context was chosen because 
it is well- established internationally that different coun-
tries vary in their approach to providing maternity care, 
the type of clinical resource inputs used to deliver specific 
types of clinical activity and in terms of the efficiency with 
which this is delivered. A review on the international 
economics of childbirth identified no accepted cost that 
was translatable across international settings8 due to 
differences in national clinical practices, outcome defi-
nitions and healthcare funding mechanisms. It was also 
necessary that the papers reported unit costs for at least 
one of the maternity pathway activities listed in table 1. 
Table 1 Key activities costed within the maternity pathway
Antenatal activity Intrapartum activity Postnatal/neonatal activity
 ► Midwife- led antenatal 
appointment.
 ► Obstetrician- led antenatal 
appointment.
 ► Glucose tolerance test.
 ► Attendance to day 
assessment unit/triage.
 ► Antenatal inpatient admission.
 ► Sonography- led ultrasound 
scan.
 ► Consultant- led ultrasound 
scan.
 ►  Induction of labour.
 ►  Augmentation of labour.
 ►  Epidural.
 ►  Normal vaginal birth.
 ►  Instrumental vaginal birth.
 ►  Elective caesarean section.
 ►  Emergency caesarean section.
 ►  Repair third/fourth degree tear.
 ►  Manual removal of placenta.
 ►  Treatment of postpartum haemorrhage (500–1500 mL).
 ►  Treatment of major obstetric haemorrhage (>1500 mL).
 ►  Examination under anaesthesia for haemorrhage.
 ► Maternal stay in postnatal 
ward (with/without baby).
 ► Maternal stay in high- 
dependency unit.
 ► Maternal stay in intensive 
care unit.
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This list contains common and presumed high- cost 
maternity activities for which the frequency of use may be 
affected by interventions introduced in research settings; 
that is, activities that were expected to impact upon cost 
estimates calculated in economic evaluations of maternity 
care. There were no specific exclusion criteria. The titles 
and abstracts were screened by the lead author (SR), and 
the remaining full texts were reviewed in full against the 
inclusion criteria by two authors (SR and LD).
Data extraction
Data were extracted from each paper by two authors 
(SR and LD) onto a prespecified study spreadsheet on 
the cost perspective taken by the study, year and method-
ology used for costing the resource use. Cost perspective 
refers to the level at which the costs are assessed; the most 
common examples are patients and families, a single 
healthcare provider, the health and/or social services and 
wider society.9 Unit costs quoted for any of the key activ-
ities listed in table 1 were collected. Costs were inflated 
to the 2018/2019 financial year using the Department of 
Health’s Pay & Price Series for financial years 2008/2009–
2015/2016 and the NHS Improvement Economic 
Assumptions for years 2016/2017 to 2018/2019.10 11
Assessment of study quality
Assessment of study quality was performed using the 
Quality of Health Economic Analyses (QHES) checklist.12 
This was designed by health economists and validated by 
both clinicians and economists with the aim of providing 
a tool suitable to evaluate all common types of health 
economic analyses by reviewers of either profession. As 
per the case study in the original QHES paper, papers 
have been assessed as high (≥75/100 points), medium 
(50–74 points) or low (<50 points) quality.
Data analysis
For the cost of each activity within the maternity pathway, 
the range, mean, SD and relative difference between the 
minimum and maximum estimates were reported. The 
distribution of costs was represented graphically on a 
scatter plot, with data divided by cost source (national 
guideline, review article and primary research study).
Simulated low- risk and high- risk patients were agreed 
through consensus of the clinical coauthors with refer-
ence to risk stratification guidance produced by NICE, to 
demonstrate the difference in cost estimates for common 
exemplar clinical scenarios when applied across the 
whole maternity pathway.13 The planned low- risk preg-
nant woman was 35 years old and multiparous, having had 
two previous vaginal births with no medical or obstetric 
complicating factors. She had an uncomplicated preg-
nancy and spontaneous vaginal birth, followed by a 6- hour 
postnatal discharge. The planned high- risk woman was 
42 years old and nulliparous, having conceived with in 
vitro fertilisation. She develops pre- eclampsia in the 35th 
gestational week and is induced at 37 weeks’ gestation. 
She labours with an epidural but requires an emergency 
caesarean section for fetal distress.
Two post hoc sensitivity analyses were conducted to 
determine; (1) the extent to which removal of low- quality 
primary research papers reduced the variability in cost 
estimates and (2) whether the variation in cost esti-
mates for each named activity was caused by the range 
of different cost perspectives used. For the first analysis, 
costs derived from published papers deemed to be of low 
quality were removed, and the effect on the mean and 
range costs per activity was described. For the second 
analysis, cost estimates for each activity included in the 
primary research articles were presented graphically, 
stratified by the perspective.
Patient and public involvement
A lay representative from Guy’s and St Thomas’ charity 
(AA) was involved in the early set- up of the DESIGN trial, 
the economic evaluation of which motivated this review. 
He is a coauthor of the DESiGN Trial Team group, who 
reviewed the final draft manuscript.
Ethical review
Ethical review is not required in the UK for systematic 
reviews.
RESULTS
Of 5081 papers identified in the electronic database 
search, 3 economic evaluations in relevant NICE guide-
lines and 10 publications identified from handsearching 
systematic reviews, 848 were duplicates and 4080 were 
excluded through screening of the titles and abstracts, 
leaving 140 full texts for screening. Following exclusion of 
papers that did not meet the inclusion criteria, 37 papers 
were included in the final review, including 27 primary 
research articles, 7 review articles and 3 economic evalua-
tions from NICE guidelines. This is represented diagram-
matically in figure 1.
The characteristics of the included studies are detailed 
in online supplemental file 3. Of the included primary 
research studies (n=27), four costed the healthcare 
activities from the perspective of the local hospital (ie, 
direct costs of procuring items and paying staff salaries at 
those hospitals), one costed from the perspective of the 
commissioner (ie, direct costs of paying the hospital for 
providing a service), two costed from the indirect societal 
perspective (ie, the wider costs to society, including work 
days lost; in one case this includes the NHS perspective) 
and the remaining studies (n=20) (including guidelines 
and review articles) costed from the NHS perspective 
only (ie, directly attributed, nationally agreed costs for 
procurement, staff salaries and so on).
In quality assessment of the 27 primary research arti-
cles, 21 were scored as high quality (≥75/100 points),14–34 
3 as medium quality (50-74/100 points)35–37 and 3 were 
scored as low quality (<50/100 points).38–40 The detailed 
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QHES evaluations are provided in online supplemental 
file 4.
Of the primary research articles (n=27), seven esti-
mated activity costs using bottom- up methodologies (ie, 
individually microcosted each item, for example, drug 
costs, equipment costs and cost per staff- hour worked), 
10 costed activities using national reference costs for 
NHS diagnosis or procedure codes and staff, 3 used other 
available literature to cost activities and the remaining 7 
studies used a combination of costing methodologies.
The cost estimates from the NICE guidelines, review arti-
cles and primary research papers (inflated to 2018/2019 
prices) are presented separately for activity items within 
antenatal, intrapartum and postnatal care within figure 2 
and in more detailed and referenced format in online 
supplemental files 5–7, respectively.
With respect to antenatal care, estimates for 20 min long 
antenatal clinic appointments were provided for midwife-
ry- led clinics (range £27.34–£146.25, mean £74.70, 5.3- fold 
difference)29 34 36 41–43 or consultant obstetrician- led clinics 
(range £43.36–£312.29, mean £144.15, 7.2- fold differ-
ence).22 25 29 34 36 41 42 44 There were only two cost estimates 
identified for glucose tolerance tests (range £13.03–£26.16, 
mean £21.80, 2.0- fold difference). A larger absolute unit cost 
range was found when estimating the cost for 1 day of an ante-
natal inpatient admission (range £298.47–£1115.87, mean 
£546.08, 3.7- fold difference).14 15 18–21 25 28 34 36–38 44–46 Simi-
larly, cost estimates for antenatal scans were variable for both 
general scans conducted by a sonographer (range £40.67–
£139.85, mean £80.86, 3.4- fold difference)29 30 35 36 42 43 45–49 
and ‘specialist’ scans, usually conducted by a fetal medicine 
consultant (range £77.82–£143.65, mean £116.34, 1.8- fold 
difference).25 29 38
When estimating cost for intrapartum activities, there 
is wide variation, and the costs for each activity item are 
generally higher than they are for antenatal or postnatal 
care. For example, the estimated cost of induction of 
labour varies between £47.56 and £805.42 (mean £450.08, 
16.9- fold difference).17 19 20 22 28 41 43 47 49–51 In some papers, 
it was clear that this variation follows decisions to cost 
the induction with or without the cost of staffing and 
antenatal admission, but this is not always the case. The 
estimated cost of an emergency caesarean section varies 
from £1056.44–£4982.21 (mean £3508.93, 4.7- fold differ-
ence)13 18–22 24 28–30 32 36 41 42 47 49–51; this includes the staffing 
and bed space required for the intrapartum admission. 
There are lower estimates that cost the surgery only 
(£318.78–£1432.71, 4.5- fold difference).15 17 33 43
Figure 1 Study selection process. NICE, National Institute for Health and Care Excellence.
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With regards to postnatal care, the inpatient post-
natal stay for a healthy woman and baby on a postnatal 
ward varies between £103.00 and £870.10 per day (mean 
£469.55, 8.4- fold difference).13–15 21 23 24 27 28 33 36 39 40 44 50 52
Through application of cost estimates to the exem-
plar activities within the care pathway for a low- risk 
multiparous woman and high- risk nulliparous woman 
and applying the lowest and highest cost estimates, we 
have demonstrated the significant effects that these cost 
variations can have on the estimated cost of care provided 
to a single woman (tables 2 and 3).
Sensitivity analysis with exclusion of the three primary 
research papers that were assessed as low quality using 
the QHES instrument resulted in only two cost estimates 
being removed from the overall results. The mean cost 
per antenatal admission day changed from £524.11 (SD: 
£239.07) to £528.51 (SD: £248.24), and the mean cost 
per day on postnatal ward changed from £471.92 (SD: 
Figure 2 Variation in extracted unit costs for activities within the maternity care pathway. ElCS, elective caesarean section; 
EmCS, emergency caesarean section; EUA, examination under anaesthesia; GTT, glucose tolerance test; HDU, high 
dependency unit; ICU, intensive care unit; IOL, induction of labour; MROP, manual removal of placenta; NICE, national institute 
for health and care excellence; PPH, postpartum haemorrhage; SVB, spontaneous vaginal birth; USS, ultrasound scan.
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£211.26) to £469.55 (SD: 219.69). There were no changes 
to intrapartum costs.
Sensitivity analysis to determine the effect of including 
a range of cost perspectives on the variation identified 
between cost estimates for each activity was conducted 
graphically, and the results are presented in online 
supplemental file 8. The majority of costs are derived 
from economic evaluations that use the perspective of 
the health service. The figure demonstrates the extent 
to which variation still exists, even for costs derived from 
studies conducted from the perspective of the health 
service. There were too few data points to examine vari-
ation across studies conducted from other perspectives.
DISCUSSION
Summary of the key findings
The aim of this report was to overview the current 
evidence on the costing of resource use within maternity 
care to inform economic evaluations of maternity inter-
ventions. We have reviewed 7 economic evaluations with 
UK costs applied following a systematic literature review, 
3 economic evaluations from UK NICE guidelines and 27 
primary research articles that have attributed unit costs to 
activity within the antenatal, intrapartum and postnatal 
pathways, specific to the UK context. We have noted wide 
ranges in published cost estimates, including a 16.9- fold 
difference between the minimum and maximum cost esti-
mates for induction of labour, despite limiting the search 
to studies within the last 10 years and inflating costs to 
2018/2019 prices.
Table 2 Estimating costs for a low- risk pregnant woman
Activity within care 
pathway*
Lowest cost 
estimate
Highest cost 
estimate
Antenatal booking 
appointment
£27.3442 £146.2534
Two sonography- led 
ultrasound scans
2× £42.2446 2× £139.8548
£84.48 £279.70
Five midwifery- led 
antenatal appointments
5× £27.3442 5× £146.2534
£136.70 £731.25
One attendance to 
maternity triage
£6.5637 £415.6525
Uncomplicated 
spontaneous vaginal birth
£1125.9533 £2572.0221
6- hour discharge £0 £0
Total £1381.03 £4144.87
*The exemplar lower risk pregnant woman was multiparous, aged 
35 years, two previous vaginal births and no medical or obstetric 
complicating factors.
Table 3 Estimating costs for a higher risk pregnant woman
Activity within care pathway* Lowest cost estimate Highest cost estimate
Antenatal booking appointment £27.3442 £146.2534
Two sonography- led ultrasound scans 2x £42.2446 2x £139.8548
£84.48 £279.70
Seven midwifery- led antenatal appointments 7x £27.3442 7x £146.2534
£191.38 £1023.75
Two consultant- led appointments 2x £43.3622 2x £312.2925
£86.72 £624.58
Three attendances to maternity triage with pre- eclampsia 3x £15.4937 3x £415.6525
£46.47 £1246.95
Two specialist growth scans 2x £77.8238 2x £127.5525
£155.64 £255.10
3- day antenatal admission 3x £298.4719 3x £1115.8714
£895.41 £3347.61
Induction of labour with 2- day antenatal admission £361.7743 £805.4219
Epidural £118.0813 £693.7020
Labour augmentation £1.1024 £189.1633
Emergency caesarean section £1056.4430 £4982.2149
3- day postnatal inpatient stay 3x £103.0024 3x £870.1021
£309.00 £2610.30
Total £3333.83 £16 204.73
*The exemplar higher risk pregnant woman was nulliparous, aged 42 years and conceived by in vitro fertilisation. Develops pre- eclampsia at 
35 weeks.
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For intrapartum costs in particular, the absolute differ-
ence between the minimum and maximum costs are 
greater, because these are usually higher cost interven-
tions. This is likely to have more of an impact on the 
results of cost- effectiveness evaluations. Even where abso-
lute cost differences are small because the activity itself 
is relatively inexpensive, for example, cost estimates for 
the glucose tolerance test (GTT), the relative difference 
shows that the maximum estimate is twice as high (or 
more) than the minimum estimate, although a low abso-
lute difference is less likely to impact when estimating the 
financial impact of new interventions.
While the estimate ranges are tighter for the unit costs 
supplied in the seven review articles, with the overall 
estimate tending towards the middle of the range of the 
primary research articles, this may be accounted for by 
both the smaller number of studies and that these studies 
are often based on estimates from the national guidelines 
and primary research articles. Wide variation also exists 
within cost estimates supplied by some NICE guidelines, 
where the same activity (eg, emergency caesarean section) 
is priced differently by economic evaluations featured in 
different guidelines.13 41 47 50
Interpretation of study findings and comparison with existing 
literature
There are several potential explanations for some of this 
variation. Variation can reflect different methodology of 
cost calculation and differing definitions of each activity, 
for example, the average cost for an inpatient admission 
varies from cost per day/night to costs estimated for a 
time- defined (eg, 3 nights) admission (although only 
costs for a single night are presented in the results). 
Costs may also vary with changing geographical perspec-
tive and varying approaches to clinical practice resource 
use between localities; it is well established that costs 
are higher in Southern England, particularly inner- city 
London.53 Methodological quality is another explana-
tion for the variation found in this review, although the 
estimates changed little after exclusion of papers deter-
mined to be of low methodological quality. Poorly applied 
methods and incomplete reporting make the results of 
economic evaluations less reliable, less comparable on a 
consistent like- with- like basis and difficult to interpret. It 
also introduces additional uncertainty when seeking to 
transfer evidence on costs to other study contexts.
Implications of this systematic review
In this paper, we have shown how variation in reported 
costs can introduce uncertainty into estimates of the 
overall cost of pregnancy management at different levels 
of pregnancy risk. This is likely to have important impli-
cations where ‘bottom- up’ costing methodologies are 
required to support the evaluation of interventions that 
are expected to change the type and volume of clinical 
activity that patients are exposed to along the pregnancy 
care pathway. This will be further magnified in cases where 
an intervention impacts on comparatively expensive areas 
of clinical activity, for example, antenatal admissions, 
method of birth and infant admission to neonatal units.
This review was originally motivated by an economic 
evaluation of the complex antenatal intervention (Growth 
Assessment Protocol)54 studied within the DEtection of 
the Small for GestatioNal age Fetus (DESiGN) trial.55 
DESiGN is a cluster- randomised controlled trial, the 
primary aim of which is to report on the clinical effec-
tiveness of the GAP programme; secondary outcomes 
include a process and economic evaluation. GAP aims 
to improve the rate of antenatal detection of small for 
gestational age fetuses.54 Estimating the financial impact 
of introducing an intervention into the antenatal pathway 
was expected to be challenging because of the bundled 
nature of national reference costs in England.4 Our 
hypothesis specified that the intervention was expected to 
increase antenatal activities such as clinic appointments 
or scans and intrapartum activities such as induction of 
labour. While these changes were expected to incur cost 
to the hospital, this would not be reflected in the bundled 
price charged to the commissioner. Itemised costs were 
therefore required.
As a result of the findings of this review, we have planned 
for sensitivity analyses to play a central role in the cost- 
effectiveness analysis of the DESiGN trial so that uncer-
tainty in the magnitude of costs linked to key resource 
use items on cost- effectiveness conclusions can be fully 
examined and reported. We recommend for other trial-
lists to do the same when conducting economic evalua-
tions in settings where widely agreed itemised costs are 
not available.
The variation in quoted costs suggests uncertainty 
around methods to calculate costs. While the included 
studies have mostly been appraised as having medium or 
high reporting quality (according to the QHES checklist), 
it was not always explicit how costs were calculated and 
exactly what was included in each estimate, for example, 
length of appointment, salary of healthcare professional 
used and inclusion of indirect costs. Guidelines on what 
should be included when calculating the cost of common 
activities, including how to account for variable staff 
salaries and indirect costs and recommendations on the 
appropriate cost perspective to choose (and report) and 
how to translate costs geographically, would be invaluable 
in achieving lower variation in published estimates.
An alternative strategy would be publication of a list of 
nationally agreed itemised costs for use in the economic 
evaluation of interventions, with guidance on which costs 
within a range of estimates are more likely to be appli-
cable to specific circumstances. This would facilitate 
greater consistency in the application of cost data across 
different evaluations. Such a list was previously available 
in England (online supplemental file 9) but has since 
been replaced by a national bundled tariff.56
Strengths and limitations
The strength of this study is in the extensive literature 
search of four relevant databases and the wide, clinically 
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generalisable (within UK maternity care) inclusion 
criteria. Unit costs extracted from published research arti-
cles were compared with one another and with summary 
costs published as part of national Health Technology 
Assessments and guidelines. Unit costs extracted from 
published reports of economic evaluations were inflated 
to 2018/2019 prices and stratified by quoted cost perspec-
tive to ensure comparability.
Due to the lack of comparability in international 
health systems and maternity reimbursement policies, 
it was not appropriate to extend the search outside of 
economic evaluations conducted within the UK. While 
the specific cost findings are only generalisable to UK 
maternity care, the overall findings regarding the chal-
lenges of estimating the financial impact of interventions 
using bundled prices, and the risk of cost variation where 
nationally agreed costs are not available, are relevant to 
maternity care providers internationally and potentially 
also to other medical specialities where bundled costs are 
commonplace.
CONCLUSIONS
Through this systematic review of economic evaluations 
within maternity care, we have described variation in costs 
applied to maternity care activities, even after controlling 
for study reporting quality and cost perspective. We have 
outlined the challenges in attributing cost to maternity 
activities, due to non- standardised activity descriptions 
and provision of composite ‘bundled’ cost estimates.
Overall, the level of variation in cost calculations is likely 
to reflect the uncertainty within the system and must be 
dealt with by conducting sensitivity analyses of economic 
evaluations. The development of nationally agreed unit 
costs for key areas of clinical activity within the pregnancy 
care pathway would serve to standardise cost- effectiveness 
evaluations of new interventions within maternity care to 
be used either for research purposes or national decisions 
regarding intervention uptake.
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Risk of bias in individual 
studies  
12 Describe methods used for assessing risk of bias of individual studies (including specification of whether this 
was done at the study or outcome level), and how this information is to be used in any data synthesis.  
8 
Summary measures  13 State the principal summary measures (e.g., risk ratio, difference in means).  8 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, including measures of 
consistency (e.g., I2) for each meta-analysis.  
8 
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-040022:e040022. 10 2020;BMJ Open, et al. Relph S
PRISMA 2009 Checklist 
Page 1 of 2  
Section/topic  # Checklist item  
Reported on 
page #  
Risk of bias across studies  15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective 
reporting within studies).  
8 
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, 
indicating which were pre-specified.  
8 
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for 
exclusions at each stage, ideally with a flow diagram.  
9 and Fig 1 
Study characteristics  18 For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) 
and provide the citations.  
Supplementary 
material 
Risk of bias within studies  19 Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).  9 
Results of individual studies  20 For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each 
intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.  
9-10 and 
Figure 2 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.  N/A 
Risk of bias across studies  22 Present results of any assessment of risk of bias across studies (see Item 15).  N/A 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 
16]).  
Figure 2 
DISCUSSION   
Summary of evidence  24 Summarize the main findings including the strength of evidence for each main outcome; consider their 
relevance to key groups (e.g., healthcare providers, users, and policy makers).  
13-15 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval 
of identified research, reporting bias).  
15 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and implications for future 
research.  
14-15 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders 
for the systematic review.  
16 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. 
doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
Page 2 of 2  
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) BMJ Open
 doi: 10.1136/bmjopen-2020-040022:e040022. 10 2020;BMJ Open, et al. Relph S
Example Search Strategy 
Database: Medline  
 ((exp PREGNANCY/ OR exp "PREGNANT WOMEN"/ OR exp "HOSPITALS, MATERNITY"/ OR exp 
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Supplementary material 3 - Characteristics of included studies 
 Article Perspective 
Original 
cost 
year Methodology 
Economic evaluations 
for  
National guidelines 
NICE - Hypertension in 
Pregnancy 1 
National 
Health Service 2010 Used NHS reference costs and costs published as parts of other trials.  
NICE - Intrapartum Care 2 
National 
Health Service 2014 
Uses the bottom-up costing calculations from a primary research study (Schroeder E, 2012) and 
revised the cost calculations by consensus with an expert committee.  
NICE - Diabetes in Pregnancy 
3 
National 
Health Service 2015 Used a combination of NHS reference costs and a bottom-up costing exercise 
Review articles 
Mistry, H (2013) 4 
National 
Health Service 
2009-
10 
Health Technology Assessment Uses NHS costs and costs from a literature review of primary research 
studies. 
Deshpande, SN (2013) 5 
National 
Health Service 2011 Weighted averages from NHS reference costs. 
Thomas, CM (2013) 6 
National 
Health Service 2011 
NHS reference costs applied to a cost-effectiveness model derived through published data sources on 
resource use.  
O'Donnell, A (2016) 7 
National 
Health Service 
2012-
13 
Health Technology Assessment uses NHS reference costs and calculations from the Personal Social 
Services Research Unit.  
Alfirevic, Z (2016) 8 
National 
Health Service 
2012-
13 
Health Technology Assessment using a de novo decision model and NHS reference/manufacturer 
costs inputs 
Farrar, D (2016) 9 
National 
Health Service 
2013-
14 
Review article for Health Technology Assessment. Uses cost from NHS reference costs, NICE 
guidelines and the Personal Social Services Research Unit. 
Gallos, I (2019) 10 
National 
Health Service 2016 
Health Technology Assessment using NHS reference costs and drug costs from the British National 
Formulary 
 
Primary research studies 
Petrou, S (2011) 11 
National 
Health Service 2008 Primary bottom-up methodology 
Eddama, O (2010) 12 Hospital 2008 Bottom-up costing exercise 
Jit, M (2010) 13 
National 
Health Service 2008 
NHS reference costs applied to a decision tree model developed through consultation of national 
hospital admission data 
Round, JA (2011) 14 
National 
Health Service 2009 Bottom-up methodology 
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Schroeder, E (2012) 15 Hospital 
2009-
10 
Costing exercise involved interviews with staff to describe resource use, costs from hospital finance 
departments and reference lists 
Essex, HN (2015) 16 
National 
Health Service 
2009-
10 NHS reference costs applied to resource use determined through a randomised controlled trial.  
Coomarasamy, A (2016) 17 
National 
Health Service 
2011-
12 
Health Technology Assessment. Uses NHS reference costs to attribute cost estimates to calculated 
resource use from a randomised controlled trial.  
Carolan-Rees, G (2015) 18 
National 
Health Service 
2011-
12 Applied NHS reference costs to resource use.  
Lain, SJ (2017) 19 
National 
Health Service 2012 NHS reference costs applied to resource use in a randomised controlled trial.  
Parisaei, M (2016) 20 
Central 
London 
Hospital 2012 Bottom-up methodology 
Ussher, M (2015) 21 
National 
Health Service 
2012-
13 National Reference costs applied to resource use in a randomised controlled trial 
Walker, KF (2017) 22 
National 
Health Service 
and personal 
social services 
2012-
13 Cost-utility analysis of a randomised controlled trial using National reference and manufacturer costs 
van der Nelson, H (2017)23 
National 
Health Service 
2012-
13 Costs taken from NHS Reference costs and the British National Formulary 
Bick, D (2017) 24 
National 
Health Service 
2013-
14 
Health Technology Assessment of a randomised controlled trial cost-effectiveness study using 
National reference costs and those from other primary research studies 
Campbell, HE (2018) 25 
Societal 
Perspective 
2013-
14 Assessed the prevalence in a UK cohort and applied costs assessed from secondary sources.  
Duckworth, S (2016) 26 Commissioner 
2013-
14 
Decision analytic model developed using data from an observational cohort study and National 
reference costs were applied 
Orlovic, M (2017) 27 
National 
Health Service 
2013-
14 
Applied NHS reference costs to resource use derived from a population study using national Hospital 
Episode Statistics data 
Vatish, M (2016) 28 
National 
Health Service 
2013-
14 Applied NHS reference costs to an economic model derived from an observational cohort study.  
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Bowers, J (2016) 29 
National 
Health Service 2014 
Used data from the Scottish Nursing and Midwifery Workload and Workforce planning project to 
develop a financial model 
Luni, Y (2017) 30 
South West 
England 
Hospital 
2014-
15 Bottom-up costing exercise 
Khan, KS (2018) 31 
National 
Health Service 
2014-
15 Bottom-up costing attached to data on resource use.  
Waugh, J (2017) 32 
National 
Health Service 
2014-
15 
Cost-effectiveness analysis conducted by NHS reference and manufacturer costs to estimated 
resource use taken from the NICE hypertension guideline. 
Jones, M (2019)33 
National 
Health Service 
2014-
15 Costs derived from NHS reference costs and the expert opinion of an NHS midwife. 
Jacklin, PB (2017) 34 
National 
Health Service 2015 Applied costs taken from published UK sources to UK and Australian cohorts 
Xydopoulos, G (2019)35 
National 
Health Service 2015 
Cost inputs derived from a series of costing templates based on NICE guidelines and NHS practice 
reports as well as other relevant scientific literature. NHS hospital tariffs could not be extrapolated to 
these costs.  
Wastlund, D (2019 - BJOG)36 
National 
Health Service 
2016-
17 
Values were identified from relevant literature by two authors, systematic reviews using UK data were 
prioritised where possible. Where multiple sources where available, those which provided ranges 
were prefered and if not, a decision was made by consensus or arbitration by the senior author.  
Wastlund, D (2019 - PLOS 
Med)37 
National 
Health Service 2017 
Costs were determined using a combination of expert opinion, relevant scientific literature and NHS 
reference costs.  
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1. Was the study objective presented in a clear, specific and 
measurable manner? (Y/N) 
2. Were the perspective of the analysis (societal, third-party payer, etc)  
and reasons for its selection stated? (Y/N) 
3. Were variable estimates used in the analysis from the best available 
source (i.e randomized control trial - best, expert opinion - worst)? 
(Y/N) 
4.  If estimates came from a subgroup analysis, were the groups 
prespecified in the beginning of the study? (Y/N) 
5. Was uncertainty handled by (1) statistical analysis to address 
random events, (2) sensitivity analysis to cover a range of 
assumptions? (Y/N) 
6. Was incremental analysis performed between alternatives for 
resources and costs? (Y/N) 
7. Was the methodology for data abstraction (including the value of 
health states and other benefits) stated? (Y/N) 
8. Did the analytic horizon allow time for all relevant and important 
outcomes? Were benefits and costs that went beyond 1 year 
discounted (3%-5%) and justification given for the discount rate? (Y/N) 
9. Was the measurement of costs appropriate and the methodology for 
the estimation of quantities and unit costs clearly described? (Y/N)  
10. Were the primary outcome measure (s) for the economic 
evaluation clearly stated and did they include the major short-term. 
Was justification given for the measures/scales used? (Y/N) 
11. Were the health outcomes measures/scales valid and reliable? If 
previously tested valid and reliable measures were not available, was 
justification given for measures and scales used? (Y/N) 
12. Were the economic model (including structure), study methods and 
analysis, and the components of numerator and denominator 
displayed in a clear, transparent manner? (Y/N) 
13. Were the choice of economic model, main assumptions, and 
limitations if the study stated and justified? (Y/N) 
14. Did the author (s) explicitly discuss direction and magnitude of 
potential biases? (Y/N) 
15. Were the conclusions/recommendations of the study justified and 
based on the study results? (Y/N) 
16. Was there a statement disclosing the source of funding for the 
study? (Y/N) 
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1. Was the study objective presented in a clear, specific and 
measurable manner? (Y/N) 
2. Were the perspective of the analysis (societal, third-party payer, etc)  
and reasons for its selection stated? (Y/N) 
3. Were variable estimates used in the analysis from the best available 
source (i.e randomized control trial - best, expert opinion - worst)? 
(Y/N) 
4.  If estimates came from a subgroup analysis, were the groups 
prespecified in the beginning of the study? (Y/N) 
5. Was uncertainty handled by (1) statistical analysis to address 
random events, (2) sensitivity analysis to cover a range of 
assumptions? (Y/N) 
6. Was incremental analysis performed between alternatives for 
resources and costs? (Y/N) 
7. Was the methodology for data abstraction (including the value of 
health states and other benefits) stated? (Y/N) 
8. Did the analytic horizon allow time for all relevant and important 
outcomes? Were benefits and costs that went beyond 1 year 
discounted (3%-5%) and justification given for the discount rate? (Y/N) 
9. Was the measurement of costs appropriate and the methodology for 
the estimation of quantities and unit costs clearly described? (Y/N)  
10. Were the primary outcome measure (s) for the economic 
evaluation clearly stated and did they include the major short-term. 
Was justification given for the measures/scales used? (Y/N) 
11. Were the health outcomes measures/scales valid and reliable? If 
previously tested valid and reliable measures were not available, was 
justification given for measures and scales used? (Y/N) 
12. Were the economic model (including structure), study methods and 
analysis, and the components of numerator and denominator 
displayed in a clear, transparent manner? (Y/N) 
13. Were the choice of economic model, main assumptions, and 
limitations if the study stated and justified? (Y/N) 
14. Did the author (s) explicitly discuss direction and magnitude of 
potential biases? (Y/N) 
15. Were the conclusions/recommendations of the study justified and 
based on the study results? (Y/N) 
16. Was there a statement disclosing the source of funding for the 
study? (Y/N) 
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1. Was the study objective presented in a clear, specific and 
measurable manner? (Y/N) 
2. Were the perspective of the analysis (societal, third-party payer, etc)  
and reasons for its selection stated? (Y/N) 
3. Were variable estimates used in the analysis from the best available 
source (i.e randomized control trial - best, expert opinion - worst)? 
(Y/N) 
4.  If estimates came from a subgroup analysis, were the groups 
prespecified in the beginning of the study? (Y/N) 
5. Was uncertainty handled by (1) statistical analysis to address 
random events, (2) sensitivity analysis to cover a range of 
assumptions? (Y/N) 
6. Was incremental analysis performed between alternatives for 
resources and costs? (Y/N) 
7. Was the methodology for data abstraction (including the value of 
health states and other benefits) stated? (Y/N) 
8. Did the analytic horizon allow time for all relevant and important 
outcomes? Were benefits and costs that went beyond 1 year 
discounted (3%-5%) and justification given for the discount rate? (Y/N) 
9. Was the measurement of costs appropriate and the methodology for 
the estimation of quantities and unit costs clearly described? (Y/N)  
10. Were the primary outcome measure (s) for the economic 
evaluation clearly stated and did they include the major short-term. 
Was justification given for the measures/scales used? (Y/N) 
11. Were the health outcomes measures/scales valid and reliable? If 
previously tested valid and reliable measures were not available, was 
justification given for measures and scales used? (Y/N) 
12. Were the economic model (including structure), study methods and 
analysis, and the components of numerator and denominator 
displayed in a clear, transparent manner? (Y/N) 
13. Were the choice of economic model, main assumptions, and 
limitations if the study stated and justified? (Y/N) 
14. Did the author (s) explicitly discuss direction and magnitude of 
potential biases? (Y/N) 
15. Were the conclusions/recommendations of the study justified and 
based on the study results? (Y/N) 
16. Was there a statement disclosing the source of funding for the 
study? (Y/N) 
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1. Was the study objective presented in a clear, specific and 
measurable manner? (Y/N) 
2. Were the perspective of the analysis (societal, third-party payer, etc)  
and reasons for its selection stated? (Y/N) 
3. Were variable estimates used in the analysis from the best available 
source (i.e randomized control trial - best, expert opinion - worst)? 
(Y/N) 
4.  If estimates came from a subgroup analysis, were the groups 
prespecified in the beginning of the study? (Y/N) 
5. Was uncertainty handled by (1) statistical analysis to address 
random events, (2) sensitivity analysis to cover a range of 
assumptions? (Y/N) 
6. Was incremental analysis performed between alternatives for 
resources and costs? (Y/N) 
7. Was the methodology for data abstraction (including the value of 
health states and other benefits) stated? (Y/N) 
8. Did the analytic horizon allow time for all relevant and important 
outcomes? Were benefits and costs that went beyond 1 year 
discounted (3%-5%) and justification given for the discount rate? (Y/N) 
9. Was the measurement of costs appropriate and the methodology for 
the estimation of quantities and unit costs clearly described? (Y/N)  
10. Were the primary outcome measure (s) for the economic 
evaluation clearly stated and did they include the major short-term. 
Was justification given for the measures/scales used? (Y/N) 
11. Were the health outcomes measures/scales valid and reliable? If 
previously tested valid and reliable measures were not available, was 
justification given for measures and scales used? (Y/N) 
12. Were the economic model (including structure), study methods and 
analysis, and the components of numerator and denominator 
displayed in a clear, transparent manner? (Y/N) 
13. Were the choice of economic model, main assumptions, and 
limitations if the study stated and justified? (Y/N) 
14. Did the author (s) explicitly discuss direction and magnitude of 
potential biases? (Y/N) 
15. Were the conclusions/recommendations of the study justified and 
based on the study results? (Y/N) 
16. Was there a statement disclosing the source of funding for the 
study? (Y/N) 
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1. Was the study objective presented in a clear, specific and 
measurable manner? (Y/N) 
2. Were the perspective of the analysis (societal, third-party payer, etc)  
and reasons for its selection stated? (Y/N) 
3. Were variable estimates used in the analysis from the best available 
source (i.e randomized control trial - best, expert opinion - worst)? 
(Y/N) 
4.  If estimates came from a subgroup analysis, were the groups 
prespecified in the beginning of the study? (Y/N) 
5. Was uncertainty handled by (1) statistical analysis to address 
random events, (2) sensitivity analysis to cover a range of 
assumptions? (Y/N) 
6. Was incremental analysis performed between alternatives for 
resources and costs? (Y/N) 
7. Was the methodology for data abstraction (including the value of 
health states and other benefits) stated? (Y/N) 
8. Did the analytic horizon allow time for all relevant and important 
outcomes? Were benefits and costs that went beyond 1 year 
discounted (3%-5%) and justification given for the discount rate? (Y/N) 
9. Was the measurement of costs appropriate and the methodology for 
the estimation of quantities and unit costs clearly described? (Y/N)  
10. Were the primary outcome measure (s) for the economic 
evaluation clearly stated and did they include the major short-term. 
Was justification given for the measures/scales used? (Y/N) 
11. Were the health outcomes measures/scales valid and reliable? If 
previously tested valid and reliable measures were not available, was 
justification given for measures and scales used? (Y/N) 
12. Were the economic model (including structure), study methods and 
analysis, and the components of numerator and denominator 
displayed in a clear, transparent manner? (Y/N) 
13. Were the choice of economic model, main assumptions, and 
limitations if the study stated and justified? (Y/N) 
14. Did the author (s) explicitly discuss direction and magnitude of 
potential biases? (Y/N) 
15. Were the conclusions/recommendations of the study justified and 
based on the study results? (Y/N) 
16. Was there a statement disclosing the source of funding for the 
study? (Y/N) 
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Supplementary material 5 - Extracted costs for antenatal care 
Activity 
costed 
Economic evaluations 
for National guidelines 
Review articles Primary research studies 
Unit costs reported Range Mean (SD) Comments 
Estimated 
cost for 
standard 
midwife 
antenatal 
appointment 
 Not costed £27.34 / 20 minute 
appointment [1],  
£224.99 / pregnancy for 
community care [2],  
£264.56 / pregnancy for 
midwife-led hospital care 
[2],  
£131.94 / hour [3] 
£76.03 / appointment [4],  
£146.25 / appointment [5], 
£60.49 / appointment [6] 
£27.34 - £146.25  £70.82 (£45.92)  Only 'per appointment' estimates 
used 
Estimated 
cost for a 
standard 
obstetric 
antenatal 
appointment 
 Not costed £114.14 / follow-up 
appointment [1],  
£515.55 / pregnancy[2] 
£43.36 [7],  
£166.68 / appointment [4],  
£312.29 / appointment [8], 
£153.94 / appointment [5], 
£124.12 / appointment [6] 
£43.36 - £312.29  £152.42 
(£89.36)  
Only 'per appointment' estimates 
used 
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Activity 
costed 
Economic evaluations 
for National guidelines 
Review articles Primary research studies 
Unit costs reported Range Mean (SD) Comments 
Estimated 
cost for any 
antenatal 
appointment 
 £95.75 / appointment 
[9] 
 Not costed £115.62 / appointment [10], 
£103.28 / appointment [11] 
£95.75 - £115.62  £104.88 
(£10.03)  
Only 'per appointment' estimates 
used 
Estimated 
cost for a 
glucose 
tolerance test 
£23.73[9]  £24.26 [3] £26.16 [12],  
£13.03 [11] 
£13.03 - £26.16  £21.80 (£5.94) 
 
Estimated 
cost for 
attendance 
to maternity 
day 
unit/triage 
 Not costed  Not costed £150.37 / visit [13],  
£415.65 / visit [8], 
£6.56 for nurse-led or £15.49 for 
doctor-led triage review [14] 
£6.56 - £415.65  £147.02 
(£190.79)  
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Activity 
costed 
Economic evaluations 
for National guidelines 
Review articles Primary research studies 
Unit costs reported Range Mean (SD) Comments 
Estimated 
cost for an 
antenatal 
inpatient 
admission 
 Not costed  Not costed £330.84 on antenatal ward or 
£1115.87 on labour ward [15],  
£366.00 / day [16],  
£1403.55 / admission [17],  
£298.47 / day [13],  
£758.18 / day for first three days 
and £448.01 / day after this [10],  
£466.91 / day [18],  
£457.75 / day [4],  
£867.59/day for first five days and 
£414.55 / day after this [8], 
 £414.55 / day [5],  
£447.12 / day [19], 
£1658.89 for standard antenatal 
stay, £304.45 for additional bed 
days [14] 
£298.47 - 
£1,115.87 
 £524.11 
(£239.07)  
Only 'per day' estimates used 
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Activity 
costed 
Economic evaluations 
for National guidelines 
Review articles Primary research studies 
Unit costs reported Range Mean (SD) Comments 
Estimated 
cost for an 
ultrasound 
scan 
(sonographer
) 
£139.85 [9] £74.90 / first scan and 
£61.83 / subsequent scans 
[1],  
£56.07 / scan [20],  
£42.24 / scan [21],  
£142.95 / 3 scans [3] 
 £57.66 / scan [22],  
£121.87 / scan [4],  
£120.49 / scan [11], 
£120.72 / scan [6], 
£112.21 / scan [23] 
£42.24 - £139.85  £86.86 (£36.13) Only 'per scan' estimates used 
Estimated 
cost for an 
ultrasound 
scan 
(specialist) 
 Not costed  Not costed  £77.82/ scan [18],  
£127.55 / scan [8], 
£143.65 / scan [6] 
£77.82 - £143.65 £116.34 (£34.32) Only 'per scan' estimates used 
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Supplementary material 6 - Extracted costs for intrapartum care 
Activity 
costed 
Economic Evaluations 
for National Guidelines 
Review articles Primary research studies 
Unit costs reported Range Mean (SD) 
Induction of 
labour 
£31.17 for drugs only [1] £33.35 for Propess, £39.53 for vaginal 
prostaglandin gel/tablet. Inpatient days 
costed separately[2],  
£361.77 for induction [3] 
£47.56 [4],  
£518.46-£805.42 in addition to cost of vaginal birth [5],  
£791.53 in addition to the cost of a vaginal birth [6],  
£33.35 for Propess pessary, £30.02 for 2 doses of Prostin [7],  
£28.94 for 2 doses of 3mg dinoprostone tablet [8] 
£290.60[9] 
£31.17 - 
£805.42 
 £469.22 (£323.86)  
Only fully-costed 
induction included in 
the summary estimates.  
Augmentation 
of labour 
 £34.98 [1],  
£56.96 [10]  
£1.90 for oxytocin, £2.97 for 
amniotomy and oxytocin[2] 
 £189.16[11],  
£1.01 for oxytocin, £0.95 for Amnihook [7],  
£1.10 for oxytocin [12] 
£1.10 - 
£189.16 
 £41.29 (£68.72) 
Epidural  £118.08 [10]  Not costed £369.89 [11],  
£693.70 in addition to the cost of a vaginal birth [6],  
£345.73 [7]  
£118.08 - 
£693.70 
 £381.85 (£266.89) 
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Activity 
costed 
Economic Evaluations 
for National Guidelines 
Review articles Primary research studies 
Unit costs reported Range Mean (SD) 
Spontaneous 
vaginal birth 
£1,170.50 [1], 
£1,762.19 [10] 
£1,888.08 [13],  
£1,222.87 if within 24 hours of 
commencing induction of labour[2], 
£1,905.40 [14] 
 £1,125.95 for birth without complication or £2,474.24 for birth 
with complication [11],  
£1,729.09 [15],  
£1,460.77-£1,812.38, dependent upon complexity [5],   
£1,782.05 [6],  
£1,473.00 [7],  
£2,572.02 [16],  
£1,943.23 [17], 
£1,607.61 [12],  
£1,648.92 [8], 
£2,721.27 [18], 
£2,586.11 [9], 
£2,343.25 [19] 
£1,125.95 - 
£2,721.27 
£1,854.15 (£486.97) 
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Activity 
costed 
Economic Evaluations 
for National Guidelines 
Review articles Primary research studies 
Unit costs reported Range Mean (SD) 
Instrumental 
birth 
£1,662.25 [1] ,  
£2,663.45 [10] 
£1,633.64 [13],  
£1194.17 more than a spontaneous 
vaginal birth [3] 
£52.64 - in addition to cost of labour [20],   
£510.31 - 677.59 for birth plus staffing and overhead costs for 
labour [11],  
£2,961.67 [15],   
£1,922.20 - £2,524.68 (dependent on complexity) [5],  
£3,100.37 [6],  
£2,003.28 [7],  
£3,100.37 [16],  
£2,866.18 [17],  
£2,045.26 [12],  
£2,056.62[8] 
£1,633.64 - 
£3,866.18 
£2,378.33 (£552.20) 
Only estimates of labour 
and birth included.  
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Activity 
costed 
Economic Evaluations 
for National Guidelines 
Review articles Primary research studies 
Unit costs reported Range Mean (SD) 
Elective 
Caesarean 
section 
£2,724.24 - £3,494.18 
[1],  
£3,923.25 [10] 
£2,166.30 [13],  
£972.05 more than a spontaneous 
vaginal birth [3], 
£3,966.92 [14] 
£1,251.51 plus staffing and overhead costs [11],  
£4,281.45 [15],  
£2,935.27 - £3,438.43(depends on complexity) [5],  
£3,380.67 [6],  
£2,983.79 [7],  
£3,402.19 [17],  
£3,385.25 [8],  
£4,120.81 [18], 
£1,056.44 [21], 
£3710.33 [9], 
£3,506.86 [19] 
£1,056.44 - 
£4,281.45 
£3,164.49 (£801.63)  
Only full estimates of 
elective Caesarean birth 
included. 
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Activity 
costed 
Economic Evaluations 
for National Guidelines 
Review articles Primary research studies 
Unit costs reported Range Mean (SD) 
Emergency 
Caesarean 
section 
£2,724.24 - £3,494.18 
[1],  
£3,923.25 [10]  
£3,541.94 [13],  
£4,143.29 [2],  
£972.05 more than a spontaneous 
vaginal birth [3] 
£318.78 - in addition to cost of labour [20],  
£1,251.51 for birth plus staffing and overhead costs for labour 
[11],  
£1,432.71 (in addition to cost of vaginal birth)  [4],  
£3,600.98 [15],  
£3,717.67 - £4,284.10 (dependent on complexity) [5],  
£4,212.22 [6],  
£3,795.33 [7],  
£4,278.73 [16],  
£4,325.86 [17],  
£4,039.93 [12],  
£4,244.57 [8],  
£4,555.92 [18], 
£1,056.44 [21], 
£4,982.21 [9], 
£4,644.47 [19]     
£2,724.24 - 
£4,982.21 
£3864.74 (£867.58)  
Only estimates of labour 
and birth included. 
Repair 3/4th 
degree tear 
 £351.95 [10]   £707.79 [11],   
£70.37 [12] 
£70.37 - 
£707.79 
£376.70 (£321.71) 
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Activity 
costed 
Economic Evaluations 
for National Guidelines 
Review articles Primary research studies 
Unit costs reported Range Mean (SD) 
Manual 
removal of 
placenta 
£152.35 for staff and 
£236.49 for 
consumables [10] 
 Not costed £819.58 [11],   
£807.09 (in addition to the cost of vaginal birth [6],   
£81.37 [12] 
£81.37 - 
£819.58 
£524.22 (£387.80) 
Postpartum 
haemorrhage 
(500-1500mL 
without 
shock) 
 £60.40 for staff and 
£40.32 for consumables 
[10] 
 Not costed  £169.34 [12] £100.72 - 
£169.34 
£135.03 (£85.18) 
Major 
obstetric 
haemorrhage 
(>1500mL) 
£950.28 for staff, 
£150.39 for one unit 
blood transfusion and 
£40.32 for consumables 
[10] 
 Not costed Not costed  Only one cost provided 
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Activity 
costed 
Economic Evaluations 
for National Guidelines 
Review articles Primary research studies 
Unit costs reported Range Mean (SD) 
Examination 
under 
anaesthesia 
for 
postpartum 
haemorrhage 
 Not costed £3,944.70 [14]  Not costed  Only one cost provided 
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Supplementary material 7 - Extracted costs for postnatal care 
Activity Costed Economic Evaluations for 
National Guidelines 
Review Articles Primary research articles 
Unit cost reported Range Mean (SD) 
Maternal 
inpatient stay on 
postnatal ward 
 £676.44 / day [1],  
£431.56 / day [2] 
£74.62 for average postnatal stay 
[3], 
£459.63/day [4] 
£330.84 / day [5],  
£549.09 / day [6],  
£112.95 / day [7],  
£870.10 / day [8],  
£1,289.57 / admission [9],  
£488.42/day [10] 
£103.00 - £757.00/day [11],  
£407.83 / day [12],  
£1,406.39 for average length of stay (<3 days) [13],  
£754.14 / standard 36-hour postnatal stay [14],  
£470.19 / day [15],  
£20.47 / hour (staff costs only) [16],  
£447.12 / day [17] 
 £103.00 – 
£870.10  
 £471.12 
(£211.26) 
Full costs only 
included.  
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Activity Costed Economic Evaluations for 
National Guidelines 
Review Articles Primary research articles 
Unit cost reported Range Mean (SD) 
Maternal 
inpatient stay in 
HDU 
£936.17 / day [1],  
£636.44/day [2] 
  £804.38 / day [5],  
£95.12 for 4 hours [7],  
£712.17 / day [18],  
£700.37/day [10], 
£890.00 / day [11],  
£587.40 / day (level 1), £734.52 / day (level 2) [15],  
£2,150.63 for first 2 days [17] 
£570.72 - 
£1075.32 
 £764.75 
(£277.20) 
Maternal 
inpatient stay in 
ITU 
£1,737.28 / day [1]  Not costed  £1,729.56 / day [19],  
£1,444.56 / day [6],  
£665.82 / day [7],  
£1,367.21 / day [18],  
£1,449.00 / day [11],  
£924.14 / day [15],  
£3,722.01 for first 2 days [17] 
£665.82 - 
£1,861.01 
£1,397.32 
(£606.35) 
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Supplementary material 9 - Summary of UK Department of Health reference costs 2015-16 and 2018-19 
Activity costed Department of Health Reference costs 
2015-16 5 
Department of Health Reference costs  
2018-19 4 
Estimated cost for antenatal 
appointment 
Non-consultant-led outpatient attendance 
for obstetrics - £117.16 
Consultant-led outpatient attendance for 
obstetrics - £141.95 
Tariff for all care within an average 
maternity pathway is costed as a 
composite, with higher prices paid for 
higher levels of obstetric complexity or 
presence of medical co-morbidities: 
£1,019-£2,713.00. 
 
Estimated cost for 
attendance to maternity day 
unit/triage 
£259.48 (NZ16Z - Day case) 
Estimated cost for an 
antenatal inpatient 
admission 
£1,133.76 for first day and £184.67 for 
every day after (NZ16Z - Antenatal Routine 
Observation) 
Estimated cost for an 
ultrasound scan  
Sonography-led: £109.07 / scan (NZ21Z) 
Specialist-led: £151.15 / scan (NZ22Z) 
Induction of labour £537.90-£850.96 in addition to cost of 
normal vaginal delivery 
Upgrades the price for vaginal birth to a 
higher level of complexity.  
  Epidural £537.90-£850.96 in addition to cost of 
normal vaginal delivery 
Spontaneous vaginal birth £1,832.10-£2,259.20 £1,957-£3,357, depends on level of 
complexity and additional activity 
Instrumental birth £2,441.01-£3,204.83 £1,957-£3,357, depends on level of 
complexity and additional activity 
Elective Caesarean section £3,383.41-£5,042.31 £3,357 
Emergency Caesarean 
section 
£4,594.77-£6,867.95 
Repair 3/4th degree tear £242.06-£762.75 in addition to cost for 
normal vaginal birth 
£0.00 - £1,400.00 (upgrades vaginal birth 
price to £3,357, if not already being paid) 
Manual removal of placenta £242.06-£762.75 in addition to cost for 
normal vaginal birth 
£0.00 - £1,400.00 (upgrades vaginal birth 
price to £3,357, if not already being paid) 
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Examination under 
anaesthesia for postpartum 
haemorrhage 
£242.06-£762.75 in addition to cost for 
normal vaginal birth 
£0.00 - £1,400.00 (upgrades vaginal birth 
price to £3,357, if not already being paid) 
Maternal inpatient stay on 
postnatal ward / maternity 
HDU 
Immediate postnatal admission included in 
cost of birth until a pre-specified length of 
stay (varies according to mode of birth). 
After this, £48.95-1,890.19/day. 
Days after 6-9 days paid at £347.00 / day 
Maternal inpatient stay in 
ITU 
£3,097.25 / day To be negotiated locally 
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